Chonluten

Chonluten is a tripeptide described in indexed literature as a bronchial epithelial cell-derived peptide bioregulator. The direct evidence base is extremely narrow: one PubMed-indexed primary study tested Chonluten alongside other Khavinson peptides in the human THP-1 monocyte/macrophage cell-line system. In that in vitro model, the authors reported modulation of proliferative signaling, reduced LPS-stimulated TNF and IL-6 expression, and reduced adhesion of peptide-treated THP-1 cells to activated endothelial cells. These findings are relevant to inflammation-pathway research but do not establish respiratory benefits, immune benefits, COPD treatment, infection protection, or human safety.

Monocyte/Macrophage Model

Chonluten was tested for regulation of inflammatory and proliferative pathways in a THP-1 monocyte/macrophage cell-line study ^[1].

Cytokine and Adhesion Signals

The study reported lower LPS-stimulated TNF and IL-6 expression and reduced adhesion of peptide-treated THP-1 cells to activated endothelial cells ^[1].

Evidence Boundary

These in vitro findings should not be translated into lung-disease, infection, or immune-treatment claims ^[1].

No Human Safety Studies

No human clinical safety studies for Chonluten were found; the direct indexed evidence is an in vitro cell-line study ^[1].

Research-Only Framing

Chonluten should be described only as a research peptide, with no recommendation for human use ^[1].